Please provide your email address to receive an email when new articles are posted on . Platelet inhibition with ticagrelor in an orodispersible tablet was similar to its standard coated form in ...

(UPDATED) Ticagrelor tablets that dissolve in the mouth are not superior to pills with standard coatings in ACS patients undergoing PCI, based on platelet reactivity, according to the small, ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) today announced that BRILINTA™ (ticagrelor) tablets, a new oral antiplatelet therapy, is now available in pharmacies in the United States.

Prasugrel may be the P2Y12 inhibitor of choice for use in combination with aspirin after PCI in patients with diabetes and ...

New Delhi, Jul 12 (PTI) Drug firm Alembic Pharmaceuticals has received tentative approval from the US health regulator for Ticagrelor tablets, used to reduce the rate of cardiovascular death and ...

WILMINGTON, Del., Dec. 16, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE: AZN) announced today that the US Food and Drug Administration (FDA) has acknowledged receipt of the company’s reply to the Complete Response ...

Alembic Pharmaceuticals has received U.S. Food and Drug Administration final approval for an abbreviated new drug application for Ticagrelor Tablets 90 mg and tentative approval for Ticagrelor Tablets ...

BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI Patients BRILINTA Recognized Across Major US Treatment Guidelines for Acute ...

WILMINGTON, Del., Dec. 16, 2010 /PRNewswire/ -- AstraZeneca announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL ...